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DNA immunization offers a novel means to induce humoral and cellular immunity in inbred or in outbred animals. Here we
have tested the efficiency of genetic immunization with hepatitis B virus (HBV) envelope-based vectors. In naive primates,
injection of a plasmid DNA encoding HBV envelope proteins induced an HBV-specific cytotoxic response and appearance of
potentially protective anti-HBs antibodies. Moreover, intramuscular and intradermal injections of a DNA expression vector
encoding an epitope of the human immunodeficiency virus envelope fused to the surface protein of the hepatitis B virus
(HBsAg) induced strong humoral and cytotoxic responses to antigenic determinants of both viruses in mice and nonhuman
primates alike. In addition, in protein-primed Rhesus monkeys B-cell memory was successfully boosted by DNA injection of
hybrid vectors and animals subsequently developed a multispecific cellular response. This suggests that DNA-based
immunization could be used to boost efficiently and broaden the immune response in individuals immunized with conven-
tional vaccines, regardless of their genetic variability. These results also indicate that it might be possible to rationally design
HBsAg-based expression vectors to induce multispecific immune responses for vaccination against hepatitis B and other
pathogens. © 1998 Academic Press
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INTRODUCTION
Genetic immunization can be defined as the in vivo
delivery of an antigen-encoding expression vector into a
given tissue in order to induce a specific immune re-
sponse. This novel form of immunization results in de
novo production of proteins that are subjected to folding,
assembly, and posttranslational modifications by the so-
matic cells of the host (Donnelly et al., 1995, 1997). This,
in turn, results in correctly processed antigen and in the
presentation of antigenic peptides by MHC class I mol-
ecules. Therefore, genetic immunization simulates the
action of live attenuated or recombinant viral vaccines.
As a consequence, this mode of immunization may
mimic natural infection and induce a protective immune
response. Most studies to date show that DNA-based
immunization results in a full range of immune re-
sponses, including neutralizing antibodies, cytotoxic T
lymphocytes (CTL), T-cell help, and protection against
challenge (Boyer et al., 1997; Cox et al., 1993; Fynan et al.,
1993; Pedroza Martins et al., 1995; Prince et al., 1997;
Ulmer et al., 1993; Xiang et al., 1994).
A further interesting feature of DNA immunization is
the ability to design expression vectors that would pro-
duce only the viral proteins or epitopes required for
protective immunity. Immunization with specific epitopes,
rather than whole proteins, avoids induction of unwanted
responses such as enhancing antibodies in human im-
munodeficiency virus (HIV) infection, which may actually
promote infection (Levy, 1993). In addition, DNA-based
immunization allows the rapid exchange of sequences
from laboratory strains to sequences derived directly
from human clinical specimens.
Our approach to the induction of epitope-specific im-
mune response has been to use fusion proteins. As a
carrier molecule we used the hepatitis B surface antigen
(HBsAg) particles. HBsAg was the first recombinant sub-
unit vaccine licensed for widespread use in humans. As
an experimental model to test epitope presentation by
HBsAg, we have used the third variable domain (V3) from
the HIV-1 envelope. We have previously shown that HIV/
HBsAg chimeric particles presenting on their surface the
V3 domain can induce HIV-specific neutralizing antibod-
ies and T-cell proliferative responses in primates
(Schlienger et al., 1992, 1994). We now explore the po-
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tential of inducing cytotoxic T-cell responses via injection
of DNA vector encoding the same fusion protein in mice
and primates.
We have previously developed a murine model for
DNA-based immunization against hepatitis B virus (HBV)
(Davis et al., 1993a). Intramuscular injection of a plasmid
DNA expression vector encoding the major surface an-
tigen of the HBV resulted in the synthesis of HBsAg by
the transfected muscle fibers and in the induction of both
anti-HBsAg (anti-HBs) antibodies and cytotoxic T lym-
phocytes (Davis et al., 1995; Michel et al., 1995). Here, as
a model we study the specificity of the responses ob-
tained upon DNA-mediated immunization using two dif-
ferent plasmid constructs encoding either the native
forms of HBsAg protein or the V3/HBsAg fusion protein.
We find that such constructs are able to induce both
humoral and cellular-specific immune responses in mice
and in naive primates and that DNA vaccines could be
used efficiently to boost animals previously immunized
with V3/HBsAg fusion proteins.
RESULTS
Humoral response in DNA-immunized mice
The efficiency of pCMV-S2.S (Michel et al., 1995) or
pCMV-V3.S DNA constructs (Fig. 1) to elicit a specific
immune response was first evaluated in mice. Mice
injected with each of the plasmid DNAs produced anti-
bodies specific to the S domain of HBsAg (Fig. 2A).
Analysis of HBsAg-specific immunoglobulins showed
that IgM predominated at one week post-DNA injection,
but the classical shift to the IgG isotype was observed
during the following weeks. IgG were first detected 2
weeks after DNA injection and increased to peak titers of
104 4 weeks after the first DNA injection. Antibody titers
induced after pCMV-V3.S injection remained stable for at
least 17 weeks and further increased 10-fold following
the second DNA injection. The kinetics of anti-HBs anti-
body production were very similar in mice injected with
either vector.
The fine specificity of the antibodies was determined
using peptides in an ELISA assay (Fig. 2B). The peptide
encompassing residues 120–145 of the HBsAg, which
has been shown previously to bind antibodies specific to
preS2 on native particles (Neurath et al., 1985), detected
antibodies in mice immunized with pCMV-S2.S vector by
2 weeks after DNA injection. After a short peak due to the
FIG. 2. Kinetics of appearance of antibodies in mice injected with
expression vectors pCMV-V3.S (solid squares) and pCMV-S2.S (open
circles). Sera were taken at different times after DNA injections and
pools were made from all sera (n 5 13) taken at a single time point. The
booster injection is indicated by an arrow. (A) IgG and IgM anti-HBs
were determined using HBsAg particles of an ayw subtype. The bound
antibodies were detected in the second step by the addition of perox-
idase-labeled goat anti-mouse IgG (continuous lines) or anti-mouse
IgM (dotted lines). (B) The binding to synthetic peptides (V3, squares;
preS2, circles) was measured from pooled sera of mice. Bound anti-
bodies were revealed by a peroxidase-labeled goat anti-mouse Ig.
End-point titers were defined as the highest serum dilution that re-
sulted in an absorbance value two times greater than that of nonim-
mune sera with a cut-off value of 0.050.
FIG. 1. Structure of the pCMV-V3.S expression vector. The amino acid
sequence of the HIV-1 Lai V3 domain fused within the preS2 domain of
the HBV middle protein (hatched region) is indicated. The two in-frame
ATG initiation codons allow the expression of the chimeric middle
protein and of the small HBV envelope protein (S). The sequences of
the murine Ld-restricted S epitope and of the Dd-restricted V3 epitope
are indicated. CMV, cytomegalovirus immediate-early promoter. HBV
39, HBV untranslated sequences and polyadenylation signal.
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induction of preS2-specific IgM (Michel et al., 1995),
antibody titers increased dramatically during the follow-
ing weeks and were slightly boosted after the second
DNA injection. The peptide encompassing residues 302–
337 of HIV-1 Lai (V3 domain) was used to detect HIV-
specific antibodies in the sera of DNA-injected mice.
Antibodies to the V3 peptide were detected from 2 weeks
after the first injection in the sera of each mouse injected
with pCMV-V3.S, and when these sera were tested on
the preS2 peptide no cross-reactivity was detected (not
shown). The anti-V3 antibodies titers were comparable to
those of preS2 antibodies induced by pCMV-S2.S injec-
tion (Fig. 2B). Then, they slightly increased over time and
were transiently boosted after the second DNA injection.
Humoral response in DNA-immunized primates
Clinically defined anti-HBs antibodies. To test whether
DNA vaccination of Rhesus macaques can result in anti-
HBs antibody titers above that known to be protective in
humans (10 mIU/ml), antibody levels in individual ma-
caque immunized with each type of construct were ref-
erenced against a standard and expressed in mIU/ml
(Table 1). Seroconversion to anti-HBs was observed in
one naive animal (Rh 50979) after the first injection of
pCMV-S2.S DNA. After the second injection, titer in-
creased to 55 mIU/ml, a titer which exceeds the protec-
tive level in humans. Then a rapid decrease in anti-HBs
was observed, and titers returned to background level.
The third injection given 6 months later was followed by
a rapid rise in antibody titers, indicating that B-cell mem-
ory had been established. After the fourth injection, anti-
HBs titers reached a level comparable to those detected
in protein-primed animals (see below). The other pCMV-
S2.S-immunized animal (Rh 49856) did not seroconvert to
anti-HBs until after the third DNA injection, and titers only
attained protective levels after the fourth DNA injection.
pCMV-V3.S DNA was given to two Rhesus macaques
(Rh 42903, Rh 35831) that were immunized 3 years pre-
viously with V3-HBsAg hybrid proteins in adjuvant
(Schlienger et al., 1992, 1994). Two weeks after the first
pCMV-V3.S DNA injection, the anti-HBs titers of these
animals had increased three- to fivefold. Titers further
increased after the second DNA injection in one animal
and in both animals after the third and fourth DNA doses.
This indicates that the immune memory induced follow-
ing protein immunization can be boosted specifically by
injection of a DNA vector encoding the same antigen.
Peptide-specific antibodies. Sera from the DNA-immu-
nized macaques were assayed for the presence of HIV-
or HBV-specific antibodies by ELISA using either HBV-
preS2 or HIV-V3 peptides as described above for mice. In
the naive animal (Rh 50979), which developed a protec-
tive level of anti-HBs antibody (Table 1), a concomitant
preS2-specific response was observed following the
second DNA injection (Fig. 3A). The antibody titers in-
creased following the third and the fourth DNA injec-
tions. In the low HBs-responder animal (Rh 49856),
preS2-specific antibodies were transiently detectable af-
ter the third injection and were boosted after the fourth
injection as observed for the anti-HBs antibodies (Figs.
3A and 3C). The kinetics of the antibody responses to
preS2 peptide and to HBsAg are comparable.
Low titers of V3-specific antibodies were detectable in
the sera from previously V3/HBsAg immunized animals
at the beginning of the DNA vaccine protocol but they
were quickly boosted in both animals following the first
TABLE 1
Anti-HBs Antibody Titers in Sera from DNA Immunized Rhesus Macaques
DNA
injection
Weeks
postinjection Rh 49856 Rh 50979 Rh 35831 Rh 42903
1° 0 0 0 518 438
2 0 0 2527 1460
6 0 8 1690 2141
2° (2 months) 0 0 3 1294 2196
3 0 55 1095 3414
9 0 6 818 ND
15 0 1 654 2103
3° (8 months) 0 0 2 669 1735
2 5 129 2574 1667
4 2 126 1846 2832
8 1 13 1276 2509
4° (12 months) 0 1 6 609 1308
2 23 1493 2196 1874
Note. Rh 49856 and Rh 50979: naive animals immunized with pCMV-S2.S. Rh 35831 and Rh 42903: protein-primed animals immunized with
pCMV-V3.S. DNA injections were given at the times indicated. Sera were collected sequentially following each DNA injection. Anti-HBs antibody titers
are expressed as milli-International Units/ml (mIU/ml) and are the mean of at least three determinations. Values above 1 mIU/ml are considered as
seroconversion.
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pCMV-V3.S DNA injection. The third and the fourth injec-
tions given at 8 and 12 months, respectively, resulted in
a 10-fold increase in anti-V3 titers (Fig. 3B). The induction
of anti-V3 antibodies did not hamper the development of
anti-HBs antibodies (Figs. 3B and 3D), indicating that the
HBs antigenic sites are not hidden by the V3 domain
presented by the hybrid fusion protein. This indicates
that priming with an epitope presented in the context of
a protein antigen can be boosted efficiently with a DNA-
based immunogen.
CTL activity in DNA-immunized animals
CTL specificity in mice. The ability of the V3 domain to
generate CTL in BALB/c mice allows rapid evaluation of
the response to chimeric DNA in a convenient animal
model (Takahashi et al., 1988). CTL activity of spleen
cells from pCMV-V3.S-immunized mice was determined
at different times following DNA injection. Splenocytes
from mice immunized once with pCMV-V3.S DNA and
stimulated in vitro with the S (Figs. 4A and 4C) or the V3
peptides (Figs. 4B and 4D) were able to lyse p815 target
cells infected with recombinant vaccinia virus express-
ing the HBV or the HIV envelope proteins, respectively,
but not p815 target cells infected with wild-type vaccinia
virus (Fig. 4, upper panel). In vivo primed and in vitro
stimulated cells were also able to lyse peptide-pulsed
but not unpulsed targets (Fig. 4, lower panel). These
results indicate that the V3 epitope is correctly pro-
FIG. 3. Kinetics of anti-peptide and anti-HBs Ig in Rhesus macaques immunized with plasmid DNA. Rh 49856 and Rh 50979, naive animals
immunized with pCMV-S2.S. Rh 35831 and Rh 42903, protein-primed animals immunized with pCMV-V3.S. Intramuscular and intradermal injections
of 1 mg of DNA were given at the times indicated by arrows. Sera were obtained at different time points and assayed individually for the presence
of antibodies reactive with synthetic peptides or with HBsAg particles. Bound antibodies were revealed by a peroxidase-labeled goat anti-human Ig.
End-point titers were the mean of at least three determinations and were defined as in Fig. 2. (A, C) Anti-preS2 and anti-HBs Ig in sera from Rh 49856
(circles) and Rh 50979 (triangles) immunized with pCMV-S2.S DNA. (B, D) Anti-V3 and anti-HBs Ig in sera from Rh 35831 (squares) and Rh 42903
(diamonds) immunized with pCMV-V3.S DNA.
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cessed when presented in the context of the HBV middle
protein. It is remarkable that in vitro stimulation with the
S peptide of pCMV-V3.S-primed spleen cells activates
cells that specifically lysed not only HBV-specific targets
but also HIV-specific targets (Figs. 4A and 4C). As a
control, p815 or p815 coated with an irrelevant peptide
was not lysed by the S-stimulated spleen cells (Fig. 4C).
When the V3 peptide was used for T-cell stimulation, this
bystander activation was not observed (Fig. 4D), or with
a much lower efficiency (not shown). Cytokine production
by in vitro S-activated T cells may result in a bystander
effect allowing the expansion of the V3-specific precur-
sor T cells.
A single injection of pCMV-V3.S DNA in BALB/c mice
was sufficient to in vivo prime detectable V3- and S-
specific CTL. This activity was detectable from 3 to 12
weeks after DNA injection (Fig. 4). Spleen cells from
control mice immunized with an irrelevant vector (pCMV-
LacZ) and stimulated with the same peptides did not lyse
the targets cells (not shown).
Induction of HIV and HBV-specific CTL in Rhesus mon-
keys. A quantification of CTL responses directed against
the HIV or HBV envelope glycoprotein was performed
using a precursor frequency analysis (CTLp). Decreasing
concentrations of peripheral blood mononuclear cells
(PBMC) were stimulated in vitro with concanavalin A
FIG. 4. Induction of CTL in BALB/c mice immunized with the pCMV-V3.S DNA vaccine. Groups of six mice were immunized once intramuscularly
with 100 mg of DNA. Spleen cells were harvested three (bottom) or 12 weeks later (top) and restimulated with the HBV-S peptide IPQSLDSWWTSL
(left) or with the HIV-V3 peptide RGPGRAFVTI (right) for 5 days and tested 2 days later for lysis of target cells. Target cells were p815 cells infected
with recombinant vaccinia virus expressing the HBV or the HIV envelope, respectively, (vv HBV-S, vv HIV Env) or with wild-type vaccinia virus (vv WT)
as indicated on the figure (top) or pulsed with peptides as shown in the bottom. The peptide I from influenza nucleoprotein (AA 147–157) was used
as H-2d control peptide for target cells. The results are representative of three experiments. The plotted lysis values at the indicated effector/target
ratios represent means of triplicates.
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(ConA) as polyclonal stimulus for T-cell proliferation and
tested for lysis of autologous B-lymphoblastoid cell lines
(B-LCL) targets infected with recombinant vaccinia vi-
ruses coding for the envelope glycoprotein of HBV or HIV.
Flow cytometry analysis performed on ConA-stimulated
bulk cultures showed that the majority of cells were
CD81 T lymphocytes (mean value 72%). The frequency of
specific HBV or HIV envelope CTLp, expressed as the
number of precursor cells for 106 PBMC, was considered
positive when the 95% confidence intervals of both val-
ues did not overlap or when it was at least 10 times
greater than CTLp specific to the control vaccinia-in-
fected targets (vv WT).
As shown in Table 2A, specific HBV CTLp were
detected in naive pCMV-S2.S immunized monkey Rh
50979, as soon as 64 days after the second DNA
injection, where the HBV-specific CTLp frequency was
66/106 PBMC (48–89) versus 2/106 PBMC (0–8) for the
control targets. This specific cellular response re-
mained detectable 29 days after the third DNA injec-
tion but disappeared 57 days after. Fewer anti-HBV
CTLp were detected in the naive pCMV-S2.S immu-
nized animal Rh 49856 after the third DNA injection.
Two or three DNA injections were sufficient to induce
an HBV-specific cytotoxic response in naive animals,
although the detection of CTLp was transient. Anti-
HBV CTLp in Rh 49856 were revealed with the recom-
binant vaccinia virus expressing the major HBV enve-
lope protein (vv HBV-S), whereas in Rh 50979 they
were detected with the recombinant vaccinia virus
expressing the middle and the major HBV envelope
proteins (vv HBV-S2.S). It is likely that the cellular
response induced in these two naive monkeys was
directed against distinct epitopes, depending on their
histocompatibility polymorphism, or that the two re-
combinant vaccinia viruses are processed in two dif-
ferent ways. As a control for antigen specificity of this
CTLp assay, no anti-HIV CTLp were found in the two
TABLE 2A
Anti-HIV or HBV CTL Precursor (CTLp) Frequencies in PBL from pCMV-S2.S
Immunized Rhesus Macaques
Note. Limiting dilution CTL assays were performed after concanavalin A stimulation of fresh PBMC isolated
from immunized monkeys at different times after DNA injection. Targets are autologous B-LCL infected with
control vaccinia virus: vv WT or recombinant vaccinia virus expressing the HIV (vv HIV-Env, vv HIV-Env*) or the
HBV envelope proteins (vv HBV-S, vv HBV-S2.S) as described under Materials and Methods. Results are
expressed as HIV- or HBV-envelope CTLp per 106 cells. Ninety-five percent confidence limits are given in
parentheses. CTLp in boxes are considered positive. ND, not done. The arrows indicate time of DNA
injections performed at months 0, 2, 8, and 12.
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pCMV-S2.S immunized monkeys, Rh 50979 and Rh
49856.
In the pCMV-V3.S immunized animals, anti-HIV CTLp
were detected after the second or the third DNA injection
(Table 2B). For Rhesus macaque Rh 42903, the specific
cellular response was detected 29 days after the third
injection and remained detectable until after the fourth
DNA injection. No anti-HBV CTLp were detected in this
monkey. In the other pCMV-V3.S immunized monkey (Rh
35831) anti-HIV and anti-HBV CTLp were detected after
the second DNA injection. The frequency of anti-HBV
CTLp remained positive after the third injection, but not
after the fourth. In the two pCMV-V3.S-immunized pri-
mates, anti-HIV CTLp were still detected after the third
and the fourth DNA injection, with a particularly high
number of CTLp for Rh 35831, where the HIV-Env*-spe-
cific CTLp frequency was 336/106 PBMC (256–441) ver-
sus 7/106 PBMC (3–15) for the control targets after the
fourth. After the third and the fourth DNA injections, two
different recombinant vaccinia viruses expressing HIV
envelope protein were used to characterize specific CTL
activities. For macaque Rh 42903, HIV-specific CTLp
were revealed only when the targets were infected with
vv HIV-Env encoding for the native gp160 of HIV-1 Lai. For
macaque Rh 35831, HIV-specific CTLp were also re-
vealed with vv HIV-Env* encoding a mutant env gene
resulting in the synthesis of an envelope protein that is
not glycosylated and not secreted (McChesney et al.,
1990). These results either suggest a difference in the
processing of the envelope polypeptide expressed by
the two vaccinia vectors used or reflect a difference in
specificity for the HIV-envelope epitopes recognized in
these two noninbred primates.
DISCUSSION
The data presented here demonstrate that immuniza-
tion of mice or primates with eukaryotic expression vec-
tors encoding the envelope protein of the hepatitis B
virus fused with an HIV epitope induces HBV and HIV-
specific B- and T-cell responses. We have chosen hep-
atitis B envelope protein as a carrier for epitope presen-
tation since we know, from our previous studies, that
antibodies and T-cell proliferative responses to the dif-
ferent viral envelope proteins can be induced following
immunization with the chimeric proteins (Michel et al.,
1988, 1990; Schlienger et al., 1992, 1994). Although anti-
body-dependent cytotoxicity was found in this model
TABLE 2B
Anti-HIV or HBV CTL Precursor (CTLP) Frequencies in PBL from pCMV-V3.S
Immunized Rhesus Macaques
Note. Please see note to Table 2A.
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(Schlienger et al., 1992, 1994) cytotoxic T lymphocytes
were not induced in primates through injection of fusion
protein in the presence of adjuvant. Our present study
demonstrates that genetic vaccination could induce CTL
as well as antibodies, de novo or in protein primed
animals.
An important feature of DNA-based immunization is
the possibility of designing vectors coding for antigens
that closely mimic the natural viral antigens and of al-
lowing the induction of a specific response, cellular as
well as humoral, in vivo. Different genetic vaccines may
be obtained quickly by simply changing antigen encod-
ing sequences. Thus, DNA vaccines could be designed
to induce multivalent immune responses. In this study,
we used the CMV promoter to express the envelope
proteins from the hepatitis B virus either in their native
forms or fused with an HIV-1 domain. As a model
epitope, we used the V3 domain of the HIV-1 envelope
protein to replace HBV-preS2 coding sequences, since
the V3 domain contains known B- and T-cell epitopes in
H-2d mice. We showed that direct injection of plasmid
DNA was highly efficient in inducing in vivo a strong
immune response to these viral antigens.
Significantly, mice receiving a single intramuscular
injection of pure DNA produced antibodies specific for
both HBV and HIV determinants. The first immunoglobu-
lins detected after DNA inoculation were of the IgM
isotype, followed by a classical shift to IgG isotype dur-
ing the next weeks. The predominance of the IgG isotype
suggests that specific helper T cells were stimulated by
DNA inoculation. These results are in agreement with
previously published data obtained in inbred mice with
HCV/HBV chimeric DNA (Major et al., 1995). Thus, ge-
netic immunization satisfies the primary goal of vac-
cines: the induction of a specific humoral response and
of immune memory.
However, in larger and noninbred animals like Rhesus
macaques, the antibody response is usually more diffi-
cult to induce and requires multiple injections (Boyer et
al., 1997; Lekutis et al., 1997; Lu et al., 1996). In one of the
naive primates immunized with the pCMV-S2.S vector,
two injections were nevertheless sufficient to induce
protective levels of anti-HBs antibodies, whereas four
doses were required in the second animal to obtain
similar results. It should be noted that antibodies de-
tected in these animals were preS2 and HBsAg specific,
as is observed in HBV-infected humans (Neurath et al.,
1985). The role of preS2 antibodies in the protection from
HBV infection is well established (Itoh et al., 1986) and in
humans these antibodies appear very early after viral
infection, sometimes even before HBsAg is detected.
In Rhesus macaques immunized 3 years earlier with
HIV/HBsAg fusion proteins, injection of pCMV-V3.S DNA
was immediately followed by a rise in anti-HBs titers,
strongly suggesting that DNA-based vaccines could be
used to boost humoral response of individuals immu-
nized with conventional vaccines. Most importantly, HIV-
specific memory is quickly stimulated following a single
DNA injection, despite the low level of preexisting anti-
bodies, further confirming that the antigen produced in
vivo from the pCMV-V3.S DNA closely mimics purified
recombinant antigen previously used for protein immu-
nization.
Cytotoxic T-lymphocyte activity appears to play an im-
portant role in resolving HBV infections (Chisari, 1995),
as well as in controlling HIV-induced disease (Haynes et
al., 1996). The ability to induce such responses remains
an important goal for developing effective therapeutics
and preventive vaccines. In this study, we analyzed the
CTL responses to HBV envelope antigens and to the
HIV-V3 domain in inbred mice and in nonhuman pri-
mates. The induction of HBsAg-specific CTL and anti-
bodies in the BALB/c mice strain following naked DNA
injection has been demonstrated previously (Davis et al.,
1995). However, HBV-specific CTL responses in primates
have not been extensively studied. Here we showed that
CTLp specific to the S or preS2 HBV antigenic domains
have been induced in naive primates through DNA-
based immunization (Table 2A). In one of the two animals
(Rh 35831, Table 2B), which had been immunized previ-
ously with protein in presence of adjuvant (Schlienger et
al., 1992), the CTL response was rapidly induced and
these cytotoxic activities reached a level comparable to
that found in naive animals. This cytotoxic response is
present despite a high level of anti-HBs antibodies in the
serum. Interestingly, in our HBV-immunized primates, the
induced specific immune response was characterized by
a transient detection of anti-HBV CTLp, while the hu-
moral response is more persistent. In contrast, in Rhesus
monkeys immunized with DNA encoding SIV envelope,
production of specific antibodies and CTL was concor-
dant but antibodies were transient while CTL persisted
(Lu et al., 1996). This difference in the quality of the
immune response induced following DNA injections may
thus be closely linked to the nature of the antigen en-
coded.
CTL have been shown in HBV-transgenic mice to
play an important role in the control of viral gene
expression via cytokine secretion (Guidotti et al., 1996).
The establishment of Th1-type responses has been
suggested to be important in the onset of HBV infec-
tions in humans (Penna et al., 1996). Thus, DNA-based
immunization holds promise not only as a preventive
tool but also as an immunotherapeutic treatment for
chronic HBV carriers.
The cellular response generated against the HIV-1 V3
domain presented in fusion with the HBV envelope pro-
tein was also analyzed. As shown after DNA injection in
BALB/c mice, the CTL epitope is correctly processed and
presented since pCMV-V3.S primed T cells efficiently
lyse targets infected with a recombinant vaccinia virus
expressing the whole HIV-1 envelope. In the two pCMV-
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V3.S-immunized primates, HIV-1 envelope-specific CTLp
were detected in the blood. Their frequencies ranged
from 13 to 336 per 106 PBMC. These frequencies are
consistent with the range of HIV-1 envelope-specific
CTLp previously reported in infected patients (Car-
michael et al., 1993; Kalams et al., 1994). In a group of
HIV-infected asymptomatic patients, the mean frequency
of anti-HIV envelope CTLp detected after specific stimu-
lation was 22 per 106 PBMC (Kundu and Merigan, 1994).
In four HIV-infected patients, with CD3 stimulation of
PBMC, anti-HIV CTLp frequencies ranged from 30 to
3800 per 106 PBMC, with lowest frequencies for enve-
lope-specific CTLp (Koup et al., 1994). In SIVmac-infected
Rhesus monkeys, SIV envelope-specific CTL were de-
tected as soon as 1 week after viral inoculation (Yasu-
tomi et al., 1993), and the frequency of anti-SIV envelope
CTLp ranged from 32 to 137 per 106 PBMC (Venet et al.,
1992). Thus, in pCMV-V3.S-immunized monkeys, enve-
lope-specific CTLp frequencies detected are consistent
with those detected in HIV-infected humans and in SIV-
mac-infected primates, even in the absence of specific
stimulation of PBMC. Considering the size of the HIV-1
envelope domain expressed from the pCMV-V3.S plas-
mid, the anti-HIV CTLp frequencies are surprisingly high,
as the animals were not preselected with respect to their
MHC haplotype. In contrast, Rhesus monkeys immu-
nized with recombinant Mycobacterium bovis carrying
one known immunodominant HIV gag epitope and
boosted with peptides displayed specific gag CTLp fre-
quencies that did not exceed 12 per 106 PBMC for this
epitope (Yasutomi et al., 1995).
An important goal in the development of an effective
viral vaccine is to induce specific cellular and humoral
responses comparable to those observed in infected
individuals. Therefore, according to the present study, by
modulating the vectors used, DNA immunization, alone
or in combination with other vaccinal approaches, pre-
sents a promising tool for the development of anti-viral
strategies.
MATERIALS AND METHODS
HBsAg-expression vectors
Two plasmids containing the envelope-coding domain
of the HBV genome (ayw subtype) under the transcrip-
tional control of the human cytomegalovirus (CMV) im-
mediate-early promoter were constructed. The plasmid
pCMV-S2.S (Michel et al., 1995) encodes the middle and
the small HBV-envelope proteins. In the other construct
pCMV-V3.S (Fig. 1), part of the amino-terminal domain of
the middle protein (preS2 domain) was substituted with
the third variable domain (V3) of the HIV-1 Lai envelope
derived from the pSV2-V3.S plasmid (Schlienger et al.,
1992). In each construct the internal ATG start codon
allowing the initiation of the small HBV protein remained
intact and the polyadenylation signal was provided by
downstream HBV untranslated sequences.
The plasmid DNA used for in vivo injection of mice
was prepared using Qiagen DNA purification columns
(Qiagen, Hilden, Germany). For Rhesus macaques endo-
toxin-free DNA was isolated by using an ultrapure-100
anion exchange chromatography column (Qiagen). Qual-
ity control of the DNA, including endotoxin testing and
high-performance liquid chromatography, was performed
as described previously (Schorr et al., 1995).
In vivo gene transfer
Each of the HBsAg expression vectors (100 mg) was
injected directly into cardiotoxin pretreated tibialis ante-
rior muscles of 6- to 8-week-old female BALB/c mice
(H-2d) as previously described (Davis et al., 1993b). A
booster injection of DNA (100 mg) was given 17 weeks
later. Cardiotoxin pretreatment was done 5 days before
DNA injection. All intramuscular injections were carried
out under anesthesia (sodium pentobarbital, 75 mg/kg,
intraperitoneally).
Four Rhesus macaques were imported from China and
housed in single cages within level 3 biosafety facilities
in accordance with EC guidelines for primates experi-
ments (Journal officiel des Communaute´s Europe´ennes,
L358, De´cembre 18, 1986). During handling, the monkeys
were anesthetized with ketamine (Imalge`ne, Rhoˆne-
Me´rieux, Lyon, France) and animals were always bled in
the morning before food distribution. Two animals (a
male Rh 35831 and a female Rh 42903), which were
immunized 3 years earlier with HIV/HBsAg fusion pro-
teins (Schlienger et al., 1992, 1994), received the pCMV-
V3.S DNA construct, whereas two naive animals (a male
Rh 50979 and a female Rh 49856) received the pCMV-
S2.S DNA construct. DNA was administered without ad-
juvant intramuscularly (500 mg in the deltoid muscle) and
intradermally (500 mg in the back) at months 0, 2, 8, and
12. The immunizations were well tolerated by all animals.
No local reactions were noticed at the sites of injections
and proximal lymph nodes were also not reactive.
Measurement of antibody production
At various times following gene transfer, blood was
collected from anesthetized animals. Anti-HBs antibod-
ies in Rhesus macaque sera were quantified using a
commercial kit (Monolisa anti-HBs, Diagnostics Pasteur,
France) and values were determined relative to the stan-
dard provided. Mean titers are expressed in milli-Inter-
national Units per milliliter (mIU/ml). ELISA assays used
to quantitate anti-HBs antibodies in the sera were per-
formed as described (Mancini et al., 1993). Briefly, HBsAg
particles were used on the solid phase and coated onto
the plates at 1 mg/ml. Antibodies to the preS2 region of
the HBV envelope or to the V3 domain of HIV-1 envelope
were quantified using synthetic peptides corresponding
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to amino acid sequences 120–145 (preS2) of the HBVayw
subtype or sequences 302–337 (V3) of the HIV-1 Lai
genotype. Adsorbed antibodies were detected with anti-
mouse IgG (Bio-Rad), anti-mouse IgM (Pierce), or anti-
mouse Ig (Amersham, UK) conjugated to horseradish
peroxidase. For Rhesus macaques anti-human Ig (Amer-
sham) conjugated to horseradish peroxidase was used
to detect specific antibodies.
Recombinant vaccinia viruses
Recombinant vaccinia viruses expressing HIV or HBV
envelope viral gene products were used to characterize
virus-specific CTL in mice and primates. The wild-type
vaccinia virus (vv WT, Copenhagen strain) and recombi-
nant vaccinia HIV-1 Lai/gp160 expression vector (vvTG-
1139 and vvTG3183) have been described. The vvTG1139
(vv HIV-Env) construct encodes the native gp160 of HIV-1
LAI and vvTG3183 (vv HIV-Env*), a mutant Env gene with
deletion of the amino-terminal signal (McChesney et al.,
1990; Rivie`re et al., 1989). The recombinant vaccinia vv
HBV-S and vv HBV-S2.S express, respectively, the small
and the small plus the middle proteins of HBV envelope
(ayw subtype) downstream from the 7.5-kDa early/late
promoter (Ando et al., 1994). They were kindly provided
by Dr. H.-J. Schlicht (University of Ulm, Germany).
Limiting dilution analysis of specific CTL precursors
in macaques
CTL assay. Frequencies of HIV- or HBV-specific CTLp
were estimated by performing limiting dilutions on
freshly isolated PBMC in complete medium (RPMIc)
composed of RPMI 1640 supplemented with 5% human
AB serum (INTS, Les Ulis, France), 2 mM L-glutamine,
nonessential amino acids, 1 mM sodium pyruvate (Gibco
BRL), and 50 IU/ml recombinant human interleukin-2
(IL-2) (RU49637, a generous gift from Dr. D. Lando, Rous-
sel Uclaf, Romainville, France). At different times after
immunization, macaque PBMC were isolated from fresh
heparinized blood by Ficoll–metrizoate gradient centrifu-
gation (Ficoll–Paque, Pharmacia, Cergy, France) and
were cultured in 24 replicate wells of round-bottom 96-
well microtiter plates (Costar, OSI, Maurepas, France) at
250, 500, 1000, 3000, 6000, 12,000, and 16,000 cells per
well in 200 ml of RPMIc supplemented with 25 mg/ml of
concanavalin A (ICN, Orsay, France) and 5 3 104 irradi-
ated (30 Gy) human lymphocytes as feeder cells. The
cultures were incubated at 37°C in an atmosphere of air
plus 5% CO2. On days 3–4, the medium was changed and
the cells were fed twice a week and then 2 days before
51Cr release assay. At weeks 2 or 3, wells were split into
three or four (50 ml each) and assayed for cytotoxicity on
51Cr-labeled autologous B-LCL infected 16 h before at a
multiplicity of infection (m.o.i.) of 5 with recombinant
vaccinia expression vector as described previously
(Buseyne et al., 1996). After a 5-h incubation at 37°C, 50
ml of supernatant was removed from each well and
counted on a beta counter. Spontaneous release was
obtained from targets incubated with medium alone and
feeder cells. It was usually less than 15% and never
exceeded 30%.
Statistical analysis. For a given target, a well was
considered positive for the presence of specific cytotoxic
activity if 51Cr release exceeded by 3 standard deviations
the mean of spontaneous release. According to the sin-
gle hit model, activated cell frequency was estimated by
the maximum likehood method (Carmichael et al., 1993;
Fazekas de st Groth, 1982). A rapid calculation of CTL
precursor frequencies and 95% confidence interval was
made available through a program kindly provided by S.
Kalams (MGH, Boston, MA) using Microsoft Excel Ver-
sion 5.0 (Kalams et al., 1994). CTLp frequencies were
expressed as the number of precursor cells for 106
PBMC. At the limit of detection, when all the wells are
negative, the CTLp frequency is one precursor for 106
PBMC.
CTL generation in mice
Groups of six mice each were immunized with DNA
vector encoding the fusion gene (pCMV-V3.S) or with a
DNA vector encoding the b-galactosidase gene (pCMV-
LacZ) as control (Davis et al., 1993b). Spleens were
removed from immunized mice at various times postin-
jection and single-cell suspensions were prepared. Cells
(107 cells/well) were suspended in 2 ml of a-MEM tissue
culture medium supplemented with 10 mM HEPES
buffer, 1 mM Na pyruvate, nonessential amino acids, 5 3
1025 M b-mercaptoethanol, antibiotics, and 10% fetal calf
serum (Gibco BRL, Cergy Pontoise, France) in 24-well
plates. Responder spleen cells were stimulated with
synthetic peptides, which are defined as CTL epitopes in
H-2d BALB/c mice and derived from the S (IPQSLDSW-
WTSL) (Ando et al., 1994; Schirmbeck et al., 1995) or from
the V3-Lai (RGPGRAFVTI) (Bergmann et al., 1993) do-
main. Both peptides were used at a concentration of 15
mg/ml for pulsing. After 5 days in culture, half of the
medium was replaced with fresh medium and the cells
were used as effectors in a standard chromium release
assay performed 2 or 3 days later. Targets were 51Cr-
labeled uninfected p815 cells, p815 cells infected 16 h
before with recombinant vaccinia virus (m.o.i. 20/1), or
p815 coated with peptides (2 mg/ml). After a 4-h incuba-
tion at 37°C, 50 ml of supernatant was removed from
each well and counted on a beta counter as described
(Buseyne et al., 1996). The percentage specific release
was calculated as (experimental release 2 spontaneous
release)/(total release 2 spontaneous release) 3 100.
Total release were measured by resuspending target
cells in lysis buffer. Spontaneous release was obtained
from targets incubated with medium alone and is usually
less than 15% of the total release.
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